HR 5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025

HR 5160 in plain English: This bill reauthorizes through FY2031 federal programs that help patients receive bone marrow and umbilical cord blood transplants from unrelated donors, administered by the Health Resources and Services Administration. It also revises the National Cord Blood Inventory program by replacing a fixed inventory goal of 150,000 units with a flexible supply level determined by HRSA, and updates the definition of high-quality cord blood units to meet current FDA and industry standards.

Stated purpose

To reauthorize through fiscal year 2031 the federal programs that help patients receive bone marrow and umbilical cord blood transplants from unrelated donors, and to update how the national cord blood supply is managed and maintained.

Key points

• Reauthorizes the C.W. Bill Young Cell Transplantation Program through FY2031
• Provides $33,009,000 per year for fiscal years 2027 through 2031 for these transplantation programs
• Replaces the fixed cord blood inventory goal of 150,000 units with a flexible supply level set by HRSA
• Requires HRSA to manage inventory size and composition to maximize clinical utility and efficiency

Arguments supporters make

• Reauthorizing these programs ensures that patients — especially those from diverse genetic backgrounds who struggle to find matched donors — continue to have access to life-saving transplants without a funding gap.
• Replacing a fixed numerical inventory goal with a flexible, science-based standard lets health officials keep the cord blood supply matched to actual medical need and current research, avoiding waste of limited resources.
• The updated quality definitions and inventory management rules bring the program in line with modern FDA standards and best practices, which could improve transplant outcomes for patients.

Arguments opponents make

• Removing the specific 150,000-unit inventory target and giving HRSA broad discretion to decide what counts as a 'sufficient supply' reduces congressional oversight and could allow the inventory to shrink without public accountability.
• Giving the Secretary authority to discontinue storage of cord blood units or transfer them based on 'operational considerations' may put smaller or specialized cord blood banks at risk, potentially reducing genetic diversity in the inventory despite stated goals.
• The incremental funding increase from $31,009,000 to $33,009,000 per year may not keep pace with rising costs, potentially limiting the program's reach even as it is nominally reauthorized.

Tradeoffs

Replacing a fixed inventory number with flexible federal discretion may allow more efficient, science-driven management, but it also reduces a concrete, measurable commitment to a minimum supply — trading legislative accountability for administrative flexibility.

Current status in Congress: Passed House.

NewsClear — neutral news & congressional tracking · Bill of the Week